The data are expressed as the crude rate (age- standardized rate) per 100000 inhabitants. Map of mortality (a) and incidence (b) of GC in Latin America. Figure 1 illustrates the different mortality and incidence rates from GC in the different countries in LA.įigure 1. GC remains common throughout many countries in Central and South America for instance, in Chile, GC is the leading cause of cancer-related death in men and women combined. In contrast to the US and EU, cancers related to infectious agents (liver cancer, stomach cancer, and cervix cancer) are exceedingly prevalent in LAP. In LA, GC is a highly relevant disease given its prevalence, incidence, and associated mortality. LA’s total population is 606 million and rising for example, the US includes 50.5 million people from LA, which represents 16.3% of the total population and is the fastest growing minority group in that country. Latin American populations (LAP) include people who live in Central and South America, as well as immigrants from these countries in the United States (US), Europe (EU), and other countries. The facts that over 70% of these cases occur in low-income countries and that the mortality rate in young cohorts in developed countries has risen suggest that gastric cancer may be among the top ten causes of death by 2030. GC remains the fourth most common cancer and is second leading cause of cancer-related death worldwide, exceeded only by lung cancer. Received 7 October 2015 accepted 1 January 2016 published 4 January 2016 Subtype of GC for enrolment, and in selecting patients according to prognosticįactors to optimize the benefits of chemotherapy. Regional, racial or molecular characteristics, to consider the molecular Implementing strategies in which patients are selected on the basis of Patients from LA are under-represented in multicenter trials ofĬhemotherapy and targeted therapies. This review examines studies conducted in Oxaliplatin or irinotecan with fluoropyrimidineĬan also be used in elderly patients who are not candidates for cisplatin, or Standard of care in light of the findings of phase III studies, whileĭocetaxel, cisplatin, and 5-fluorouracil (5-FU) are alternatives for patients Cisplatin and fluoropyrimidine continue to be the However, the best regimen for specific populations, suchĪs LA, is as yet unknown. Chemotherapy is the standard treatmentįor advanced-stage GC. Latin America (LA), the burden of this disease is higher and is the leadingĬause of cancer death in some countries. Neoplasm and the second leading cause of cancer-related death worldwide. Gastric cancer (GC) is the fourth most common